- Home
- USA vs BEAM Comparison
USA vs BEAM Comparison
Compare USA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USA
- BEAM
- Stock Information
- Founded
- USA 1986
- BEAM 2017
- Country
- USA United States
- BEAM United States
- Employees
- USA N/A
- BEAM N/A
- Industry
- USA Finance Companies
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USA Finance
- BEAM Health Care
- Exchange
- USA Nasdaq
- BEAM Nasdaq
- Market Cap
- USA N/A
- BEAM 1.6B
- IPO Year
- USA N/A
- BEAM 2020
- Fundamental
- Price
- USA $6.90
- BEAM $19.88
- Analyst Decision
- USA
- BEAM Strong Buy
- Analyst Count
- USA 0
- BEAM 11
- Target Price
- USA N/A
- BEAM $48.90
- AVG Volume (30 Days)
- USA 880.5K
- BEAM 2.0M
- Earning Date
- USA 01-01-0001
- BEAM 08-05-2025
- Dividend Yield
- USA 9.66%
- BEAM N/A
- EPS Growth
- USA N/A
- BEAM N/A
- EPS
- USA N/A
- BEAM N/A
- Revenue
- USA N/A
- BEAM $63,578,000.00
- Revenue This Year
- USA N/A
- BEAM N/A
- Revenue Next Year
- USA N/A
- BEAM $8.82
- P/E Ratio
- USA N/A
- BEAM N/A
- Revenue Growth
- USA N/A
- BEAM N/A
- 52 Week Low
- USA $5.62
- BEAM $13.53
- 52 Week High
- USA $7.09
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- USA 67.83
- BEAM 67.72
- Support Level
- USA $6.64
- BEAM $16.59
- Resistance Level
- USA $6.74
- BEAM $17.38
- Average True Range (ATR)
- USA 0.07
- BEAM 1.09
- MACD
- USA 0.02
- BEAM 0.24
- Stochastic Oscillator
- USA 95.12
- BEAM 93.78
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.